Today, the journal Cureus — which is no stranger to Retraction Watch — unveiled what they are calling a “Wall of Shame,” which “highlights authors and reviewers who have committed egregious ethical violations as well as the institutions that enabled them.”
Two professors and two former graduate students are banned from funding by the Japan Society for the Promotion of Science (JSPS) following findings by Nagoya University of misconduct and lack of supervision.
As we reported last month, Nagoya found that Yuuta Yano, a graduate student in Kenichiro Itami’s lab, had forged large swaths of data and had thrown away lab notebooks to escape detection. Itami, along with Hideto Ito, had asked for an investigation into the team’s work after retracting papers in Natureand ACS Applied Nano Materials on which Yano was an author.
A cancer researcher faked data in a grant application, her PhD thesis, and seven published papers, according to the U.S. Office of Research Integrity.
Toni Brand, who earned her PhD from the University of Wisconsin and served as a postdoc at the University of California, San Francisco (UCSF), “engaged in research misconduct by knowingly or recklessly falsifying or fabricating western blot data, by reusing and relabeling data to represent expression of proteins in control experiments measuring the purity of cytoplasmic and nuclear cell fractionation, measurements of proteins of interest, and measurements of the same protein under different experimental conditions or loading controls,” the ORI said in a report published today.
A researcher who agreed to a dozen years of supervision for NIH-funded research was fired from the Albert Einstein College of Medicine at the end of 2019, Retraction Watch has learned.
As we reported last week, the U.S. Office of Research Integrity (ORI) found that the researcher, Hui (Herb) Bin Sun, and a colleague, Daniel Leong, faked data in 50 figures in 16 NIH grant applications going back to 2013. The ORI findings are dated March 21, 2022.
Apologies in advance for the fact that this post is really just for the science publishing completists out there. But we know you’re out there.
Last week, Endpoints News, STAT and a few other outlets reported that Biogen had, in Endpoint’s words, “finally” published the key data behind the approval of Aduhelm by the U.S. FDA – a controversial green light, to say the least. The company had previously withdrawn the manuscript from JAMA because the journal had – gasp! – demanded edits, Axiosreported last year.
Critics pointed out that the Journal of Prevention of Alzheimer’s Disease (JPAD) – where the study was eventually published – was a far cry from JAMA, and suggested that the paper was subjected only to peer-review lite.
A pair of researchers at the Albert Einstein College of Medicine in New York faked data in 50 figures in 16 NIH grant applications for six years starting in 2013, according to new findings from the U.S. Office of Research Integrity (ORI).
According to the ORI, Daniel Leong, a former lab tech at Einstein,
intentionally, knowingly, or recklessly falsified and/or fabricated Western blot and histological image data for chronic deep tissue conditions including osteoarthritis (OA) and tendinopathy in murine models by reusing image data, with or without manipulating them to conceal their similarities, and falsely relabeling them as data representing different experiments in fifty (50) figures included in sixteen (16) PHS grant applications. In the absence of reliable image data, the figures, quantitative data in associated graphs purportedly derived from those images, statistical analyses, and related text also are false.